

**D. Iñigo de la Lastra**

Director General de Mercados Secundarios  
CNMV  
Edison, 4  
28006 Madrid

Barcelona, 12 de marzo de 2015

## HECHO RELEVANTE

Muy Sr. mío:

A los efectos de dar cumplimiento a lo establecido en la Ley 24/1988, de 28 de julio, reguladora del Mercado de Valores y disposiciones concordantes, LABORATORIO REIG JOFRE, S.A., ("Reig Jofre" o "la Sociedad"), anteriormente denominada NATRACEUTICAL, S.A., informa que el próximo **lunes 23 de marzo, a las 11:00 am**, la Sociedad realizará una presentación de los resultados proforma de 2014, tras la reciente fusión entre Reig Jofre y Natraceutical.

La presentación se realizará en directo, en inglés, vía webcast y será atendida por parte de Reig Jofre por:

- Ignasi Biosca, Consejero Delegado
- Gabriel Roig, Director General Financiero
- Gloria Folch, Directora de Relación con Inversores

Dada la reciente fusión entre Reig Jofre y Natraceutical y, por ello, la ausencia de informes de analistas actualizados sobre la nueva compañía, la Sociedad facilita a continuación una breve nota descriptiva del valor, que incluye los datos de conexión vía web a dicha presentación.

Sin otro particular, reciba un cordial saludo,

Adolf Rousaud  
Secretario del Consejo de Administración  
Laboratorio Reig Jofre, S.A.

## A new company following the merger with Natraceutical

Since December 31, 2014, Reig Jofre is the result of the merger between the Spanish listed company Natraceutical SA and the family-owned pharmaceutical company Laboratorio Reig Jofre SA.

Following the merger, Natraceutical SA changed its name to Laboratorio Reig Jofre SA and it trades now under the ticker RJF (former NTC).

The new Reig Jofre is the fifth largest Spanish pharmaceutical company by turnover listed on the Spanish stock market.

Reig Jofre specializes in the research, development, manufacture and marketing of medicines and nutritional supplements, as well as in specialized contract manufacturing. The company directs its R&D to develop new pharmaceutical products either internally or in partnership with bio-ventures and research centers, as well as variations in the formulation of known active principles in order to modify their release, improve their dosage and to obtain new routes of administration or indications. It also develops and manufactures injectable generics for licensing. Reig Jofre has an outstanding experience in the development and manufacture of lyophilized injectables, beta lactam antibiotics, topical dermatological products and nutraceuticals.

Prior to the merger, Natraceutical's figures in 2013 stood at: 31.4 M€ turnover; 2.6 M€ EBITDA and 2.1 M€ profit before taxes. After the merger, the new company stands at 152.5 M€ turnover; 15.0 M€ EBITDA and 9.2 M€ profit before taxes.

Headquartered in Barcelona (Spain), the new Reig Jofre has strengthened its market position by diversifying its product portfolio in the segments of pharma (69% of combined sales in 2013), OTC (16%) and food supplements (15%), as well as its international presence, whose sales outside Spain represent 64% of the joint turnover and are distributed between France (17%), Germany (10%), UK (9%), Sweden (6%) and about fifty other countries on the five continents (21%).

CEO: Ignasi Biosca / CFO: Gabriel Roig / IR: Gloria Folch

Keep informed of the latest news about Reig Jofre by subscribing to <http://www.reigjofre.com/en/subscription-center>

Av. de les Flors  
08970 Sant Joan Despí  
Barcelona, Spain  
T. +34 93 480 67 10

[www.reigjofre.com](http://www.reigjofre.com)

### FIRST LIFE WEBCAST

**Topic:** Merger and 2014 results

**Date:** March 23, 2015

**Time:** 11:00 am CET

**Language:** English only

**Hosted by:** CEO, CFO and IR

**Link:** <http://goo.gl/ewCAF7>

Questions may also be sent prior to March 23, to [investors@reigjofre.com](mailto:investors@reigjofre.com)

**Bloomberg / Reuters:** RJF SM / RJFE.MC

**Outstanding shares:** 1,264,284,408

**Share price\*:** 0.299 €

**Market cap:** 378 M€

**Free float:** 13%

\* March 4, 2015

	2012	2013	2014	CAGR 12-14
<b>Sales</b>	<b>135.1</b>	<b>152.9</b>	<b>152.5</b>	6.2%
Gross margin	81.1	93.4	97.2	9.5%
% sales	60%	61%	64%	
<b>EBITDA</b>	<b>11.5</b>	<b>18.2</b>	<b>15.0</b>	14.2%
% sales	9%	12%	10%	
<b>EBIT</b>	<b>6.3</b>	<b>13.4</b>	<b>10.0</b>	26.0%
% sales	5%	9%	7%	
<b>EBT</b>	<b>2.7</b>	<b>12.0</b>	<b>9.2</b>	84.6%
% sales	2%	8%	6%	
<b>Net profit</b>	<b>2.9</b>	<b>8.6</b>	<b>6.9</b>	54.3%

Non-audited proforma figures. In million euros

	2014
NFD/EBITDA	0.99 x
NFD/Equity	3.9%
NFD/BV	12.6%
EBITDA/Fin. int.	16.2 x
EV/Sales	2.6 x
EV/EBITDA	26.2 x
EV/EBIT	42.7 x
PER	54.8 x
P/FCF	35.1 x
P/BV	3.2 x
EPS	0.005€
BVPS	0.093€
DPS	-
FCF yield	2.9%
ROCE	7.5%